An­thos to stop fac­tor XI tri­al in atri­al fib­ril­la­tion ear­ly af­ter 'over­whelm­ing ben­e­fit'

An­thos Ther­a­peu­tics an­nounced Mon­day morn­ing that it is stop­ping a Phase II study of its next-gen­er­a­tion an­ti­co­ag­u­lant abelacimab in atri­al fib­ril­la­tion as a re­sult of “over­whelm­ing ben­e­fit.”

The de­ci­sion came af­ter an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee rec­om­mend­ed the com­pa­ny and its aca­d­e­m­ic col­lab­o­ra­tor — the TI­MI Study Group from Brigham and Women’s Hos­pi­tal and Har­vard — to stop the study ear­ly since pa­tients in the treat­ment arm saw a sub­stan­tial re­duc­tion in bleed­ing events com­pared to those in the con­trol arm, who re­ceived John­son & John­son’s Xarel­to.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.